1 month ago
Latino voters helped propel Donald Trump back to the White House. Now, they are turning on him, according to a new NBC News/Telemundo poll — a shift that gives Democrats a major opportunity to capitalize in a 2026 election that could hinge on states and districts with sizable Latino populations.
Like the broader electorate, Latino voters are racked by major concerns about high prices and Trump’s approach to immigration enforcement. The president’s approval rating sits at 27% among Latino voters. Two-thirds say his administration’s deportation policies have gone too far and three-quarters disapprove of how he has handled the economy and the cost of living.
There are clear signs his party is paying the price.
A greater share of Latino voters hold negative views of the Republican Party than at any time since 2016, and Democrats have leads on issues like dealing with the economy, immigration, the cost of living, corruption and healthcare. Two years ago, Latino voters gave Trump a 4-point edge over then-Vice President Kamala Harris on handling the economy. Today, they give Democrats a 21-point advantage on the same question.
Against that backdrop, Democrats have a 24-point lead on whom Latino voters want to see in control of Congress, 59%-35%.
#latino
Like the broader electorate, Latino voters are racked by major concerns about high prices and Trump’s approach to immigration enforcement. The president’s approval rating sits at 27% among Latino voters. Two-thirds say his administration’s deportation policies have gone too far and three-quarters disapprove of how he has handled the economy and the cost of living.
There are clear signs his party is paying the price.
A greater share of Latino voters hold negative views of the Republican Party than at any time since 2016, and Democrats have leads on issues like dealing with the economy, immigration, the cost of living, corruption and healthcare. Two years ago, Latino voters gave Trump a 4-point edge over then-Vice President Kamala Harris on handling the economy. Today, they give Democrats a 21-point advantage on the same question.
Against that backdrop, Democrats have a 24-point lead on whom Latino voters want to see in control of Congress, 59%-35%.
#latino
2 months ago
On September 8, 2026, CNBC reported that Novartis' failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY), both of which are racing to prove that lowering lipoprotein(a), or Lp(a). It can meaningfully reduce heart attacks and strokes.
Analysts said Amgen's olpasiran faces the clearest negative read-through given its similar trial design. Lilly's lepodisiran is being tested in a broader patient population that could limit how directly Novartis' failure applies. It is also described as less material to Lilly's overall valuation than pelacarsen was for Novartis.
Copyright: stocking / 123RF Stock Photo
Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY) could still succeed where Novartis failed. Pelacarsen's failure does not establish that lowering Lp(a) cannot reduce cardiovascular events. **** ysts noted that Novartis' trial faced a high statistical hurdle and that Amgen's olpasiran and Lilly's lepodisiran have produced stronger Lp(a) reductions in earlier studies. Both companies also continue testing their drugs in specific patient populations with high Lp(a). It leaves room for their trials to produce different outcomes from Novartis' study.
Lilly's lepodisiran faces a less direct read-through than Amgen's olpasiran. **** ysts view Amgen's olpasiran as the closest comparison to pelacarsen because the programs use similar trial designs. Lilly's lepodisiran is being tested in an overall patient population. It could make Novartis' failure less directly applicable. **** ysts also view lepodisiran as less material to Lilly's overall valuation than pelacarsen was to Novartis. It reduces the potential financial impact of an unsuccessful outcome.
#lepodisiran #less
Analysts said Amgen's olpasiran faces the clearest negative read-through given its similar trial design. Lilly's lepodisiran is being tested in a broader patient population that could limit how directly Novartis' failure applies. It is also described as less material to Lilly's overall valuation than pelacarsen was for Novartis.
Copyright: stocking / 123RF Stock Photo
Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY) could still succeed where Novartis failed. Pelacarsen's failure does not establish that lowering Lp(a) cannot reduce cardiovascular events. **** ysts noted that Novartis' trial faced a high statistical hurdle and that Amgen's olpasiran and Lilly's lepodisiran have produced stronger Lp(a) reductions in earlier studies. Both companies also continue testing their drugs in specific patient populations with high Lp(a). It leaves room for their trials to produce different outcomes from Novartis' study.
Lilly's lepodisiran faces a less direct read-through than Amgen's olpasiran. **** ysts view Amgen's olpasiran as the closest comparison to pelacarsen because the programs use similar trial designs. Lilly's lepodisiran is being tested in an overall patient population. It could make Novartis' failure less directly applicable. **** ysts also view lepodisiran as less material to Lilly's overall valuation than pelacarsen was to Novartis. It reduces the potential financial impact of an unsuccessful outcome.
#lepodisiran #less
2 months ago
Toledo, Ohio-based Welltower Inc. (WELL) is a heavyweight in healthcare real estate. With a market cap of $170.2 billion, the REIT owns and manages properties across the United States, Canada, and the United Kingdom. Its portfolio is centered on senior housing communities, outpatient medical centers, and long-term care facilities.
Companies worth $10 billion or more are generally referred to as "large-cap stocks." Welltower fits right into that category, with its market cap exceeding the threshold, reflecting its substantial size, influence, and dominance in the real estate sector. By partnering with healthcare providers and senior living operators, Welltower is positioned to capitalize on the growing demand for care as populations age.
How to Play SNPS Stock as Layoffs Hit Synopsys
Micron Stock More Than Tripled in 2026. Now Taiwan Strike Threat Could Shake the AI Boom.
Dear Adobe Stock Fans, Mark Your Calendars for September 10
#estate
Companies worth $10 billion or more are generally referred to as "large-cap stocks." Welltower fits right into that category, with its market cap exceeding the threshold, reflecting its substantial size, influence, and dominance in the real estate sector. By partnering with healthcare providers and senior living operators, Welltower is positioned to capitalize on the growing demand for care as populations age.
How to Play SNPS Stock as Layoffs Hit Synopsys
Micron Stock More Than Tripled in 2026. Now Taiwan Strike Threat Could Shake the AI Boom.
Dear Adobe Stock Fans, Mark Your Calendars for September 10
#estate
2 months ago
On August 10, Joe Gomes from ***** le Capital reiterated his Outperform rating on CoreCivic Inc. (NYSE:CXW). In the process, the ***** yst increased his target price on the stock from $35 to $42, resulting in a revised upside potential in excess of 24% based on stock's closing price on August 27. This upward adjustment in price target came after an impressive second quarter print above management estimates. Let's explore the underlying drivers of this outperformance, and which additional factors are expected to shape up investor sentiment toward the stock.
Earlier in August, the company reported its second quarter results which exceeded management's expectations. Topline figures were recorded at $684.9 million, up by 27.3% compared to Q2 2025. Adjusted EBITDA of $109.4 million exhibited 5.9% year-on-year growth, while adjusted diluted EPS of $0.38 reflected a 5.6% growth compared to the same period last year. Such expansion in adjusted diluted EPS was supported by lower operating costs and slightly higher ICE populations, while strong federal revenue also contributed to growth. Following the quarter and subsequent facility sales, management raised its full-year 2026 guidance.
During 2026, CoreCivic has been focusing on strengthening its financial position while expanding its footprint as a federal detention operator. The company generated $734 million in gross proceeds from sales of Prairie Correctional Facility and Midwest Regional Reception Center, to the Department of Homeland Security. It expects to continue to operate both facilities under current arrangements, and was also awarded a new ICE contract to operate the 1,600 bed Prairie Correctional Facility till August 2031. The contract award offers potential for $75 million in revenue boost in the future once fully activated, with no material impact expected during 2026.
CoreCivic can benefit from this demand tailwind without the time and capital required to construct entirely new facilities, although activating idle sites still involves staffing and start-up costs. It also strengthens the company's position as a trusted partner for federal detention requirements, and might create potential opportunities for more contracts in the future.
The company has also taken an aggressive approach toward debt reduction and returning capital to shareholders. On August 10, it entered a $500 million accelerated share repurchase agreement, supported by the proceeds from recent facility sales. A portion of those sale proceeds was also utilized for $608.5 million debt repayment, which included early redemption of senior notes that were due in 2027.
#price
Earlier in August, the company reported its second quarter results which exceeded management's expectations. Topline figures were recorded at $684.9 million, up by 27.3% compared to Q2 2025. Adjusted EBITDA of $109.4 million exhibited 5.9% year-on-year growth, while adjusted diluted EPS of $0.38 reflected a 5.6% growth compared to the same period last year. Such expansion in adjusted diluted EPS was supported by lower operating costs and slightly higher ICE populations, while strong federal revenue also contributed to growth. Following the quarter and subsequent facility sales, management raised its full-year 2026 guidance.
During 2026, CoreCivic has been focusing on strengthening its financial position while expanding its footprint as a federal detention operator. The company generated $734 million in gross proceeds from sales of Prairie Correctional Facility and Midwest Regional Reception Center, to the Department of Homeland Security. It expects to continue to operate both facilities under current arrangements, and was also awarded a new ICE contract to operate the 1,600 bed Prairie Correctional Facility till August 2031. The contract award offers potential for $75 million in revenue boost in the future once fully activated, with no material impact expected during 2026.
CoreCivic can benefit from this demand tailwind without the time and capital required to construct entirely new facilities, although activating idle sites still involves staffing and start-up costs. It also strengthens the company's position as a trusted partner for federal detention requirements, and might create potential opportunities for more contracts in the future.
The company has also taken an aggressive approach toward debt reduction and returning capital to shareholders. On August 10, it entered a $500 million accelerated share repurchase agreement, supported by the proceeds from recent facility sales. A portion of those sale proceeds was also utilized for $608.5 million debt repayment, which included early redemption of senior notes that were due in 2027.
#price
2 months ago
Hospitals thought losing hundreds of billions in Medicaid funding through GOP-led cuts last year was bad. But coming regulations from the Trump administration could slash their funding even deeper than Congress did.
Two recently proposed rules from the Centers for Medicare and Medicaid Services would cost hospitals hundreds of billions of dollars more, hospital executives told POLITICO. The rules, which target taxes states use to get more federal Medicaid dollars — and which yield higher payments to hospitals — have prompted hospitals to launch another major lobbying blitz after record spending last year.
"Our core message to CMS is to stick to the statute. Congress cut enough," said Robert Nelb, director of policy at America's Essential Hospitals, which represents hospitals serving large Medicaid populations.
"There's no need to cut any more out of the Medicaid system at a time when the safety net is really struggling," Nelb added.
If the rules are finalized and they lose hundreds of billions on top of Congress' funding cuts, hospitals say they'll be forced to reduce services, lay off workers, consolidate operations or shutter entirely. Some systems are already doing so, telling POLITICO they've cut staff, ended contracts and slashed hospital beds in response to predicted losses.
#congress
Two recently proposed rules from the Centers for Medicare and Medicaid Services would cost hospitals hundreds of billions of dollars more, hospital executives told POLITICO. The rules, which target taxes states use to get more federal Medicaid dollars — and which yield higher payments to hospitals — have prompted hospitals to launch another major lobbying blitz after record spending last year.
"Our core message to CMS is to stick to the statute. Congress cut enough," said Robert Nelb, director of policy at America's Essential Hospitals, which represents hospitals serving large Medicaid populations.
"There's no need to cut any more out of the Medicaid system at a time when the safety net is really struggling," Nelb added.
If the rules are finalized and they lose hundreds of billions on top of Congress' funding cuts, hospitals say they'll be forced to reduce services, lay off workers, consolidate operations or shutter entirely. Some systems are already doing so, telling POLITICO they've cut staff, ended contracts and slashed hospital beds in response to predicted losses.
#congress
2 months ago
Leading U.S. medical groups are urging people to get updated flu and COVID-19 vaccinations this fall, banding together Wednesday to issue shot guidelines — and highlight the science behind them — saying they hope to ease confusion caused by the Trump administration's changing advice.
Flu vaccinations are beginning and COVID-19 shots are starting to arrive after the Food and Drug Administration approved this year's updated versions last week. Winter also brings another vaccine-preventable risk called RSV. Exactly who should get one or all of these vaccines, and when?
That advice usually comes from the Centers for Disease Control and Prevention, with help from its independent advisers. But despite no new scientific evidence, Trump health officials last year began pulling back on some longstanding recommendations for fall virus protection and routine children's vaccinations. And that advisory panel, which influences state and insurance vaccine policies, is caught in a court battle. The CDC didn't respond to questions about any new fall guidance but suggested on its website that doctors follow last year's flu recommendations.
Doctors' groups are filling the gap: the American Academy of Pediatrics, American Academy of Family Physicians, American College of Obstetricians and Gynecologists, and the Infectious Diseases Society of America each released vaccination guidelines for their patient populations.
"There's been a lot of confusion and chaos regarding vaccine recommendations," said Dr. Sandra Fryhofer, of the American Medical **** ociation.
#vaccinations #medical
Flu vaccinations are beginning and COVID-19 shots are starting to arrive after the Food and Drug Administration approved this year's updated versions last week. Winter also brings another vaccine-preventable risk called RSV. Exactly who should get one or all of these vaccines, and when?
That advice usually comes from the Centers for Disease Control and Prevention, with help from its independent advisers. But despite no new scientific evidence, Trump health officials last year began pulling back on some longstanding recommendations for fall virus protection and routine children's vaccinations. And that advisory panel, which influences state and insurance vaccine policies, is caught in a court battle. The CDC didn't respond to questions about any new fall guidance but suggested on its website that doctors follow last year's flu recommendations.
Doctors' groups are filling the gap: the American Academy of Pediatrics, American Academy of Family Physicians, American College of Obstetricians and Gynecologists, and the Infectious Diseases Society of America each released vaccination guidelines for their patient populations.
"There's been a lot of confusion and chaos regarding vaccine recommendations," said Dr. Sandra Fryhofer, of the American Medical **** ociation.
#vaccinations #medical
3 months ago
By Yoruk Bahceli, Ben Welsh, Dhara Ranasinghe and Rocky Swift
LONDON/NEW YORK/TOKYO, August 20 (Reuters) - U.S. debt has topped $40 trillion for the first time, underscoring the pressures on the world's major economies to fund ever-increasing spending demands -- from ageing populations to climate change and defence.
This year, the Iran war has rekindled inflation risks, while damage wrought by Europe's increasingly volatile weather is a further strain on public finances.
No wonder perhaps that U.S. 30-year Treasury yields have risen to their highest since 2007, prompting government action to contain rising borrowing costs. ******* anese borrowing costs are also near their highest in three decades and even Germany -- whose debt load is considerably lighter -- has seen its yields jump to the highest levels since 2011.
A high debt burden that brings higher borrowing costs risks hurting living standards by constraining spending and capping growth. Sovereign debt sets the benchmark for borrowing costs for companies and other loans, including household mortgages.
#spending #since
LONDON/NEW YORK/TOKYO, August 20 (Reuters) - U.S. debt has topped $40 trillion for the first time, underscoring the pressures on the world's major economies to fund ever-increasing spending demands -- from ageing populations to climate change and defence.
This year, the Iran war has rekindled inflation risks, while damage wrought by Europe's increasingly volatile weather is a further strain on public finances.
No wonder perhaps that U.S. 30-year Treasury yields have risen to their highest since 2007, prompting government action to contain rising borrowing costs. ******* anese borrowing costs are also near their highest in three decades and even Germany -- whose debt load is considerably lighter -- has seen its yields jump to the highest levels since 2011.
A high debt burden that brings higher borrowing costs risks hurting living standards by constraining spending and capping growth. Sovereign debt sets the benchmark for borrowing costs for companies and other loans, including household mortgages.
#spending #since
3 months ago
NEW YORK (AP) — Ancient mummy DNA recovered in Chile has yielded the firmest evidence yet that European colonization brought smallpox to the Americas.
Smallpox was one of the deadliest diseases in human history before it was eradicated in 1980, largely thanks to vaccination. For centuries, the virus had killed about one-third of the people it infected and left most survivors with deep and sometimes disfiguring scars.
Outbreaks struck Asia and Europe and eventually spread to the Americas, where colonial writings, administrative records and missionary reports documented how it killed millions and devastated Indigenous populations who had never been exposed to the virus.
Now there's scientific evidence for the spread: An ******* ysis of Chilean mummies provides the strongest genetic link yet to the virus as it existed outside of the Americas, and provides a better picture of how it reached remote populations through colonization, said geneticist Shigeki Nakagome with Trinity College Dublin.
In the new study, Nakagome and colleagues examined 13 bone samples previously collected from an archaeological site at Camarones, in northern Chile.
#populations
Smallpox was one of the deadliest diseases in human history before it was eradicated in 1980, largely thanks to vaccination. For centuries, the virus had killed about one-third of the people it infected and left most survivors with deep and sometimes disfiguring scars.
Outbreaks struck Asia and Europe and eventually spread to the Americas, where colonial writings, administrative records and missionary reports documented how it killed millions and devastated Indigenous populations who had never been exposed to the virus.
Now there's scientific evidence for the spread: An ******* ysis of Chilean mummies provides the strongest genetic link yet to the virus as it existed outside of the Americas, and provides a better picture of how it reached remote populations through colonization, said geneticist Shigeki Nakagome with Trinity College Dublin.
In the new study, Nakagome and colleagues examined 13 bone samples previously collected from an archaeological site at Camarones, in northern Chile.
#populations
3 months ago
In this episode of Behind the Ticker, Brad Roth, CIO of Thor Financial Technologies, chats with Young Jae Lee, Senior Investment Manager at Pictet ******* et Management about what traditional emerging market ETFs capture, what they don't, and why the Pictet Emerging Markets Rising Economies ETF (RISE) offers true diversification.
Prefer to watch this conversation? You can do that here or on our YouTube channel.
Emerging markets ETFs are secretly tech bets. The top five holdings in the MSCI EM benchmark mirror the top five in the S&P 500 almost sector-for-sector. Buy traditional EM ETFs and you're really just doubling down on the same tech risk.
Pictet's new ETF, RISE, kicks out the biggest names in EM. It excludes Korea, Taiwan, and China entirely, even though those three countries make up more than 70% of the standard benchmark. The bet: real emerging-market exposure means growing working-age populations, not aging economies riding on legacy index weight.
Demographics are EM's version of AI. Borrowing from the Solow Growth Model, Young Jae Lee argues population growth is what actually drives GDP in developing markets like India, Brazil, Indonesia, and Mexico. That demographic engine deserves the same portfolio spotlight in EM allocations that AI gets in US ones.
#traditional #market
Prefer to watch this conversation? You can do that here or on our YouTube channel.
Emerging markets ETFs are secretly tech bets. The top five holdings in the MSCI EM benchmark mirror the top five in the S&P 500 almost sector-for-sector. Buy traditional EM ETFs and you're really just doubling down on the same tech risk.
Pictet's new ETF, RISE, kicks out the biggest names in EM. It excludes Korea, Taiwan, and China entirely, even though those three countries make up more than 70% of the standard benchmark. The bet: real emerging-market exposure means growing working-age populations, not aging economies riding on legacy index weight.
Demographics are EM's version of AI. Borrowing from the Solow Growth Model, Young Jae Lee argues population growth is what actually drives GDP in developing markets like India, Brazil, Indonesia, and Mexico. That demographic engine deserves the same portfolio spotlight in EM allocations that AI gets in US ones.
#traditional #market
4 months ago
Eli Lilly and Company (NYSE:LLY) is one of the high growth stocks to buy right now. On June 14, Eli Lilly announced positive results from the Phase 3 BRUIN CLL-322 clinical trial, which evaluated the addition of Jaypirca (pirtobrutinib) to a time-limited venetoclax and rituximab regimen for patients with relapsed or refractory chronic lymphocytic leukemia/CLL or small lymphocytic lymphoma/SLL. The study met its primary endpoint, showing that the pirtobrutinib combination reduced the risk of disease progression or death by 45% compared to the control arm of venetoclax and rituximab alone.
The trial enrolled 639 patients, nearly 80% of whom had been previously treated with a covalent BTK inhibitor, making the findings highly relevant to current clinical practices. At a median follow-up of 27.3 months, the median progression-free survival/PFS in the pirtobrutinib arm had not been reached, compared to 39.7 months in the control arm. These benefits were consistent across various high-risk patient subgroups, and the pirtobrutinib combination also showed a significant advantage in the time to next treatment.
The safety profile of the regimen was consistent with the known profiles of the individual medicines, with minimal additive toxicity observed when adding pirtobrutinib. Discontinuation rates due to treatment-related adverse events were similar between the two study arms. Based on these findings, Eli Lilly and Company (NYSE:LLY) plans to submit the data to global regulatory authorities with the goal of expanding the use of Jaypirca as a potential new standard of care in previously treated CLL/SLL populations.
Eli Lilly and Company (NYSE:LLY) is a healthcare company that develops human pharmaceutical products, including cardiometabolic health, oncology, and immunology products.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
The trial enrolled 639 patients, nearly 80% of whom had been previously treated with a covalent BTK inhibitor, making the findings highly relevant to current clinical practices. At a median follow-up of 27.3 months, the median progression-free survival/PFS in the pirtobrutinib arm had not been reached, compared to 39.7 months in the control arm. These benefits were consistent across various high-risk patient subgroups, and the pirtobrutinib combination also showed a significant advantage in the time to next treatment.
The safety profile of the regimen was consistent with the known profiles of the individual medicines, with minimal additive toxicity observed when adding pirtobrutinib. Discontinuation rates due to treatment-related adverse events were similar between the two study arms. Based on these findings, Eli Lilly and Company (NYSE:LLY) plans to submit the data to global regulatory authorities with the goal of expanding the use of Jaypirca as a potential new standard of care in previously treated CLL/SLL populations.
Eli Lilly and Company (NYSE:LLY) is a healthcare company that develops human pharmaceutical products, including cardiometabolic health, oncology, and immunology products.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
4 months ago
BeOne Medicines AG (NASDAQ:ONC) is one of the most promising healthcare stocks according to Wall Street ******* ysts. On June 3, Citizens kept its Market Outperform rating and $396 price target on BeOne Medicines AG (NASDAQ:ONC). The firm made the call after BeOne presented robust tumor clinical data at the American Society of Clinical Oncology (ASCO) 2026 conference.
Citizens said that data for three drugs in BeOne's pipeline caught its attention. The first was BGB-43395, which BeOne is testing in a common and hard-to-treat form of breast cancer known as HR+/HER2- metastatic breast cancer. The other two are BG-C9074, an antibody-drug conjugate targeting ovarian cancer maintenance and BGB-B2033, a bispecific antibody that BeOne is evaluating in liver cancer.
Citizens noted that in its view, what makes the pipeline noteworthy is that each of these drugs is going after patient populations where current treatments are either too toxic, face resistance problems, or simply do not exist. For that reason, the firm sees BeOne at an inflection point where its tumor strategy is no longer just theoretical.
The firm said it arrived at the $396 price target through a discounted earnings and revenue multiple ******* ysis. It added that it has confidence in BeOne funding its ambitious pipeline because the company holds $4.85 billion in cash, carries more cash than debt, and generates gross profit margins of 88%.
BeOne Medicines AG (NASDAQ:ONC) is a commercial-stage biopharmaceutical company focused on developing novel therapies for the treatment of cancer. Its pipeline includes candidates designed to address unmet needs in solid tumors and hematologic malignancies.
Citizens said that data for three drugs in BeOne's pipeline caught its attention. The first was BGB-43395, which BeOne is testing in a common and hard-to-treat form of breast cancer known as HR+/HER2- metastatic breast cancer. The other two are BG-C9074, an antibody-drug conjugate targeting ovarian cancer maintenance and BGB-B2033, a bispecific antibody that BeOne is evaluating in liver cancer.
Citizens noted that in its view, what makes the pipeline noteworthy is that each of these drugs is going after patient populations where current treatments are either too toxic, face resistance problems, or simply do not exist. For that reason, the firm sees BeOne at an inflection point where its tumor strategy is no longer just theoretical.
The firm said it arrived at the $396 price target through a discounted earnings and revenue multiple ******* ysis. It added that it has confidence in BeOne funding its ambitious pipeline because the company holds $4.85 billion in cash, carries more cash than debt, and generates gross profit margins of 88%.
BeOne Medicines AG (NASDAQ:ONC) is a commercial-stage biopharmaceutical company focused on developing novel therapies for the treatment of cancer. Its pipeline includes candidates designed to address unmet needs in solid tumors and hematologic malignancies.
5 months ago
Local ratings are in for the United States men’s national soccer team’s World Cup match against Paraguay, and the cities most interested in the game may not be the ones you expect.
According to Michael Mulvihill, the President of Insights and ***** ytics at Fox Corporation, Kansas City had the highest English-language ratings for United States-Paraguay.
Kansas City recorded a 9.2 rating and a 29 share. A rating is the percentage of total households in a market that tuned into the game, while share is the percentage of households watching TV that were watching the game. So 9.2% of Kansas City households watched United States-Paraguay, and 29% of households watching TV in Kansas City were tuned into the match.
The story is slightly different when Spanish viewership is included. Combined English- and Spanish-language ratings show Los Angeles topping all markets with a 13.4 rating and a 42 share. For comparison, throughout the entire 2025 World Series (Los Angeles Dodgers-Toronto Blue Jays), Los Angeles averaged a 17.6 rating and a 53 share.
The combined English + Spanish ratings generally highlight cities with large Hispanic populations (Los Angeles, Miami, and Houston are the top three). But the English-language ratings are far more interesting. Boston was No. 2 with an 8.6 rating, while San Diego, Dallas, and St. Louis tied at 7.3.
According to Michael Mulvihill, the President of Insights and ***** ytics at Fox Corporation, Kansas City had the highest English-language ratings for United States-Paraguay.
Kansas City recorded a 9.2 rating and a 29 share. A rating is the percentage of total households in a market that tuned into the game, while share is the percentage of households watching TV that were watching the game. So 9.2% of Kansas City households watched United States-Paraguay, and 29% of households watching TV in Kansas City were tuned into the match.
The story is slightly different when Spanish viewership is included. Combined English- and Spanish-language ratings show Los Angeles topping all markets with a 13.4 rating and a 42 share. For comparison, throughout the entire 2025 World Series (Los Angeles Dodgers-Toronto Blue Jays), Los Angeles averaged a 17.6 rating and a 53 share.
The combined English + Spanish ratings generally highlight cities with large Hispanic populations (Los Angeles, Miami, and Houston are the top three). But the English-language ratings are far more interesting. Boston was No. 2 with an 8.6 rating, while San Diego, Dallas, and St. Louis tied at 7.3.
5 months ago
We just covered Forget AI: Legendary Value Investor Seth Klarman Is Buying These 10 Value Stocks in 2026. Molina Healthcare (NYSE:MOH) ranks #8 (see Seth Klarman Is Buying These 5 Value Stocks in 2026).Baupost's Stake: $84,460,000Molina Healthcare (NYSE:MOH) is a managed care company focused on government-sponsored health programs — Medicaid, Medicare, and the ACA Marketplace. Its moat lies in long-standing state government contracts, deep expertise serving low-income populations, and an infrastructure built specifically around Medicaid managed care.The stock has been hammered amid Medicaid rate adjustments and elevated medical costs. But bulls argue this is a cyclical trough, not a structural problem. Medicaid managed care has a well-documented cycle — costs overshoot state reimbursement rates, companies take losses, states adjust rates higher, and margins recover. Molina Healthcare's (NYSE:MOH) CEO has explicitly called 2026 the margin trough.Q1 2026 provided the first hard evidence of recovery. Adjusted EPS came in at $2.35, crushing the $1.29 consensus, sending the stock up 15% in a day. Bank of America issued a rare double upgrade to Buy, lifting its price target to $250 and projecting EPS could reach $30 by 2029 — nearly twice the Street consensus of $17.32.
While we acknowledge the potential of MOH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Disclosure: None. Follow Insider Monkey on Google News.
While we acknowledge the potential of MOH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Disclosure: None. Follow Insider Monkey on Google News.
5 months ago
Is ZBH a good stock to buy? We came across a bullish thesis on Zimmer Biomet Holdings, Inc. on X.com by MoneyShow. In this article, we will summarize the bulls' thesis on ZBH. Zimmer Biomet Holdings, Inc.'s share was trading at $87.27 as of June 8th. ZBH's trailing and forward P/E were 22.62 and 10.46 respectively according to Yahoo Finance.
ldutko/Shutterstock.com
Zimmer Biomet Holdings, Inc. (ZBH) is positioned as a leading player in the global musculoskeletal healthcare market, with dominant share in hip and knee replacements supported by a broad portfolio of orthopedic implants, surgical products, and enabling technologies. The company continues to benefit from favorable long-term industry trends, including aging populations, rising healthcare access, and growing demand for joint reconstruction procedures.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
ldutko/Shutterstock.com
Zimmer Biomet Holdings, Inc. (ZBH) is positioned as a leading player in the global musculoskeletal healthcare market, with dominant share in hip and knee replacements supported by a broad portfolio of orthopedic implants, surgical products, and enabling technologies. The company continues to benefit from favorable long-term industry trends, including aging populations, rising healthcare access, and growing demand for joint reconstruction procedures.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
5 months ago
In some ways, Mexican food has actually become as American as apple pie.
Mexican culture is widely established in America’s restaurants. Some 11% of restaurants in the United States serve Mexican food, according to a Pew Research Center ***** ysis of data from SafeGraph, which curates information about millions of places of interest around the globe, and the user review site Yelp.
And while Texas and California have the most Mexican restaurants, most of the United States has access to the cuisine.
"This ***** ysis finds that 85% of U.S. counties have at least one Mexican restaurant. In turn, the counties that don’t have Mexican restaurants tend to have small populations. The 15% of counties without any Mexican restaurants have about 4 million people living in them. That is just 1% of the total U.S. population," according to Pew Research.
The popularity of Mexican cuisine, however, has made the ***** e incredibly competitive. It has led to many chains growing, then stumbling and closing restaurants. El Torito, for example, grew to nearly 200 locations in the late '80s, and after recent closures, it's down to only 21, according to its website.
Mexican culture is widely established in America’s restaurants. Some 11% of restaurants in the United States serve Mexican food, according to a Pew Research Center ***** ysis of data from SafeGraph, which curates information about millions of places of interest around the globe, and the user review site Yelp.
And while Texas and California have the most Mexican restaurants, most of the United States has access to the cuisine.
"This ***** ysis finds that 85% of U.S. counties have at least one Mexican restaurant. In turn, the counties that don’t have Mexican restaurants tend to have small populations. The 15% of counties without any Mexican restaurants have about 4 million people living in them. That is just 1% of the total U.S. population," according to Pew Research.
The popularity of Mexican cuisine, however, has made the ***** e incredibly competitive. It has led to many chains growing, then stumbling and closing restaurants. El Torito, for example, grew to nearly 200 locations in the late '80s, and after recent closures, it's down to only 21, according to its website.
5 months ago
Valued at a market cap of $140.9 billion, Welltower Inc. (WELL) is a real estate investment trust (REIT) that stands as one of the world's largest healthcare infrastructure investors. The Toledo, Ohio-based company’s real estate footprint operates exclusively at the intersection of housing, hospitality, and healthcare, with a massive focus on rental housing for aging populations alongside wellness housing and outpatient medical facilities.
Companies valued at $10 billion or more are typically classified as “large-cap stocks,” and WELL fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the REIT - healthcare facilities industry. The company’s core specialty centers on its proprietary Data Science and Machine Learning platform, which powers the "Welltower Business System." This specialized technology stack uses predictive ******* ytics to optimize micromarket site selection, aggressively drive down property operating expenses, and maximize revenue per occupied room (RevPOR) across its senior living communities, fundamentally positioning the firm as a tech-driven operator wrapped in a real estate shell.
BNP Paribas Initiates Coverage on CoreWeave. That Means CRWV Stock Could Soar 71% from Here.
Super Micro Computer Just Unveiled the New AMD Helios Platform. What That Means for SMCI Stock.
Honeywell Stock Is Likely to Reward Shareholders Following Quantinuum IPO, Split
Companies valued at $10 billion or more are typically classified as “large-cap stocks,” and WELL fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the REIT - healthcare facilities industry. The company’s core specialty centers on its proprietary Data Science and Machine Learning platform, which powers the "Welltower Business System." This specialized technology stack uses predictive ******* ytics to optimize micromarket site selection, aggressively drive down property operating expenses, and maximize revenue per occupied room (RevPOR) across its senior living communities, fundamentally positioning the firm as a tech-driven operator wrapped in a real estate shell.
BNP Paribas Initiates Coverage on CoreWeave. That Means CRWV Stock Could Soar 71% from Here.
Super Micro Computer Just Unveiled the New AMD Helios Platform. What That Means for SMCI Stock.
Honeywell Stock Is Likely to Reward Shareholders Following Quantinuum IPO, Split
5 months ago
The autonomous trucking race has a new entrant with a distinctly old-school playbook. Bot Auto, fresh off completing its first fully humanless commercial load on a public highway, is betting its next chapter on a freight industry veteran who has spent nearly three decades learning how to build trucking networks.
Brett Suma is joining as president and chief operating officer, bringing with him David Stemm as vice president of commercial operations and Jessica Kane as vice president of commercial finance. The trio founded TrailerHawk.ai together before Wabash acquired it in 2025. They are now reuniting to tackle one of the industry’s most complex operational challenges: turning a technological milestone into a repeatable commercial business.
“We have proven that humanless commercial truckloads are possible, but we understand that technology alone cannot drive value creation,” said Dr. Xiaodi Hou, founder and CEO of Bot Auto. “This industry is complex for good reasons, and building a scalable autonomous freight product requires humility, flexibility, and relentless creativity.”
Suma’s freight education started at age 19, working nights at Knight Transportation to pay for college. From the beginning, trucking had him hooked. From 1999 through the company’s explosive growth period in the early 2000s, he watched the founders build a methodical freight network to feed their growing fleet. It started by identifying corridors with the right freight density, matching them to driver populations, then constructing facilities to support 125 to 150 trucks per market.
“It was very formulaic,” Suma said. “You had to identify a corridor that fit your network that had access to a certain level of inbound and outbound freight to be able to support the driver population that you would need in order to support the actual construction of the facility.”
Brett Suma is joining as president and chief operating officer, bringing with him David Stemm as vice president of commercial operations and Jessica Kane as vice president of commercial finance. The trio founded TrailerHawk.ai together before Wabash acquired it in 2025. They are now reuniting to tackle one of the industry’s most complex operational challenges: turning a technological milestone into a repeatable commercial business.
“We have proven that humanless commercial truckloads are possible, but we understand that technology alone cannot drive value creation,” said Dr. Xiaodi Hou, founder and CEO of Bot Auto. “This industry is complex for good reasons, and building a scalable autonomous freight product requires humility, flexibility, and relentless creativity.”
Suma’s freight education started at age 19, working nights at Knight Transportation to pay for college. From the beginning, trucking had him hooked. From 1999 through the company’s explosive growth period in the early 2000s, he watched the founders build a methodical freight network to feed their growing fleet. It started by identifying corridors with the right freight density, matching them to driver populations, then constructing facilities to support 125 to 150 trucks per market.
“It was very formulaic,” Suma said. “You had to identify a corridor that fit your network that had access to a certain level of inbound and outbound freight to be able to support the driver population that you would need in order to support the actual construction of the facility.”
8 months ago
Older Humpbacks Prove Better at Wooing Mates
As humpback whale populations recover, researchers are gaining a richer understanding of these wondrous creatures. A new study suggests it may take years for humpbacks to learn how to successfully serenade a mate.
Before being decimated by whaling a century ago, there were around 120,000 humpbacks globally, but over decades their numbers were reduced by as much as 95 percent. Since countries agreed to ban commercial whaling in 1986, humpback whales have been rebounding and have nearly recovered in some regions.
For a new study, researchers foll
As humpback whale populations recover, researchers are gaining a richer understanding of these wondrous creatures. A new study suggests it may take years for humpbacks to learn how to successfully serenade a mate.
Before being decimated by whaling a century ago, there were around 120,000 humpbacks globally, but over decades their numbers were reduced by as much as 95 percent. Since countries agreed to ban commercial whaling in 1986, humpback whales have been rebounding and have nearly recovered in some regions.
For a new study, researchers foll
10 months ago
A curious and paradoxical intolerance for lactose across the South Asian subcontinent could help explain why the ability for adults to consume fresh milk from other animals developed in other populations.
Researchers from the University of California, Berkeley, led a team of scientists in a genome-wide study of people across the Asian subcontinent to better understand how and why the ability to digest the sugar common in dairy products spread.
Despite being the world's biggest producers and consumers of dairy, most adults in India, Pakistan, and Bangladesh do not produce enough lactase, an e
Researchers from the University of California, Berkeley, led a team of scientists in a genome-wide study of people across the Asian subcontinent to better understand how and why the ability to digest the sugar common in dairy products spread.
Despite being the world's biggest producers and consumers of dairy, most adults in India, Pakistan, and Bangladesh do not produce enough lactase, an e
11 months ago
MANHATTAN (KSNT) – This year is the 50th anniversary of the first case of herbicide resistance in Kansas, and Kansas State University is reflecting on what has been done and what’s left to do with the issue.
The first known case of herbicide resistance in Kansas came in 1976 when populations of kochia, an early spring weed/herb native to Europe and Asia, growing near railroads were found to be resistant to atrazine, a popular herbicide used in corn and sorghum fields. Today, this resistant kochia can be found across the state.
Kansas Livestock ***** ociation approves policies for 2026
Since
The first known case of herbicide resistance in Kansas came in 1976 when populations of kochia, an early spring weed/herb native to Europe and Asia, growing near railroads were found to be resistant to atrazine, a popular herbicide used in corn and sorghum fields. Today, this resistant kochia can be found across the state.
Kansas Livestock ***** ociation approves policies for 2026
Since
1 yr. ago
at the least, and for one, wars, and weapons manufacturing are perfect business for high profits off public tax budgets for the rich people
the same with the business of fear and scare
that is used to control and rule over populations, while exploiting them economically
the same with the business of fear and scare
that is used to control and rule over populations, while exploiting them economically
